Insmed Announces Results Of IPLEX(TM) Phase II Trial In Myotonic Muscular Dystrophy

Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.